Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Role Of P-Glycoprotein And Breast Cancer Resistance Protein-1 In The Brain Penetration And Brain Pharmacodynamic Activity Of The Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941

L. Salphati, Leslie B. Lee, Jodie Pang, E. Plise, X. Zhang
Published 2010 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) is a novel small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway currently evaluated in the clinic as an anticancer agent. The objectives of this study were to determine in vitro whether GDC-0941 was a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) and to investigate the impact of these transporters on the pharmacokinetics, brain penetration, and activity of GDC-0941 in FVBn mice (wild-type) and Mdr1a/b(−/−), Bcrp1(−/−), and Mdr1a/b(−/−)/Bcrp1(−/−) knockout mice. Studies with Madin-Darby canine kidney cells transfected with P-gp or Bcrp1 established that this compound was a substrate of both transporters. After administrations to mice, GDC-0941 brain-to-plasma ratio ranged from 0.02 to 0.06 in the wild-type and Bcrp1(−/−) mice and was modestly higher in the Mdr1a/b(−/−) mice, ranging from 0.08 to 0.11. In contrast, GDC-0941 brain-to-plasma ratio in Mdr1a/b(−/−)/Bcrp1(−/−) triple knockout mice was 30-fold higher than in the wild-type mice. The plasma clearance of GDC-0941 was similar in wild-type and all knockout mice, ranging from 15 to 25 ml/(min · kg) in the wild-type mice and from 18 to 35 ml/(min · kg) in the knockout mice. Exposure after oral administration was comparable in the four strains of mice. The PI3K pathway was markedly inhibited in the brain of Mdr1a/b(−/−)/Bcrp1(−/−) mice for up to 6 h postdose, as evidenced by a 60% suppression of the phosphorylated Akt signal, whereas no inhibition was detected in the brain of wild-type mice. The concerted effects of P-gp and Bcrp1 in restricting GDC-0941 access and pathway modulation in mouse brain may have implications for the treatment of patients with brain tumors.
This paper references
PGlycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan
NA de Vries (2007)
The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
L. Zhou (2009)
Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
H. Kodaira (2010)
Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme
S. Liebner (2000)
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
H. Zhang (2003)
Blood–brain barrier and chemotherapeutic treatment of brain tumors
N. D. de Vries (2006)
A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.
D. Sarker (2009)
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
J. Luo (2003)
Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios
J. C. Kalvass (2007)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
J. Huse (2010)
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
D. Koul (2010)
Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
L. Salphati (2009)
PIK3CA mutations in glioblastoma multiforme
C. Hartmann (2005)
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
J. Polli (2009)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
A. Folkes (2008)
P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan
N. D. de Vries (2007)

This paper is referenced by
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Chung-Pu Wu (2017)
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.
Timothy Heffron (2012)
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood–Brain Barrier without restriction by ABCB1 and ABCG2
F. Li-n (2013)
Revisiting the role of ABC transporters in multidrug-resistant cancer
R. Robey (2018)
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
K. Natarajan (2012)
Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport
Khine Myint (2015)
Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
J. Ware (2013)
Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
Rajneet K. Oberoi (2016)
Regulation of ABCG2 Expression in the Lactating Mammary Gland
A. Wu (2014)
The ABCG2 Multidrug Transporter
Agnès Basseville (2016)
Bioinspired Biomaterials: Advances in Tissue Engineering and Regenerative Medicine
H. J. Chun (2020)
Deciphering the molecular signaling pathways in breast cancer pathogenesis and their role in diagnostic and treatment modalities
A. T. Prabha (2017)
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human
L. Salphati (2011)
Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole
Y. Nagasaka (2014)
Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
F. Li-n (2013)
Influence of active efflux transport on the distribution of targeted agents to brain tumors
Rajneet K. Oberoi (2014)
Protein-Based Drug Delivery in Brain Tumor Therapy.
Hae Won Hwang (2020)
Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
L. Salphati (2012)
Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
E. Choo (2014)
Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging
L. Salphati (2014)
Obstacles to Brain Tumor Therapy: Key ABC Transporters
J. Wijaya (2017)
Breast Cancer from Molecular Point of View: Pathogenesis and Biomarkers
S. Ostad (2011)
ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors
P. Zhang (2015)
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
D. Sarker (2014)
Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human
L. Salphati (2012)
Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
Chung-Pu Wu (2020)
Semantic Scholar Logo Some data provided by SemanticScholar